Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
Recombinant human follitropin are drugs that mimic the physiological effects of gonadotropins, used therapeutically mainly as fertility medication for ovarian hyperstimulation and ovulation induction.
For patients undergoing superovulation or assisted reproductive techniques, such as in vitro fertilization-embryo transfer (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian tube transplantation (ZIFT), recombinant human follitropin can stimulate multifollicular development.
Market Analysis and Insights: Global Recombinant Human Follitropin Market
The global Recombinant Human Follitropin market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
Global Recombinant Human Follitropin Scope and Market Size
Recombinant Human Follitropin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human Follitropin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
RHF-α
RHF-β
Urofollitropin
Segment by Application
Freeze-Dried Powder Injection
Injection
By Company
Changchun High & New
Merck Serono
Merck(USA)
Gen Sci
LIVZON
IBSA
Reproductive Health
Ferring
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
For patients undergoing superovulation or assisted reproductive techniques, such as in vitro fertilization-embryo transfer (IVF), gamete intrafallopian transfer (GIFT), and zygote intrafallopian tube transplantation (ZIFT), recombinant human follitropin can stimulate multifollicular development.
Market Analysis and Insights: Global Recombinant Human Follitropin Market
The global Recombinant Human Follitropin market is valued at US$ XX million in 2019. The market size will reach US$ XX million by the end of 2026, growing at a CAGR of XX% during 2021-2026.
Global Recombinant Human Follitropin Scope and Market Size
Recombinant Human Follitropin market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Recombinant Human Follitropin market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2016-2027.
Segment by Type
RHF-α
RHF-β
Urofollitropin
Segment by Application
Freeze-Dried Powder Injection
Injection
By Company
Changchun High & New
Merck Serono
Merck(USA)
Gen Sci
LIVZON
IBSA
Reproductive Health
Ferring
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
